Aevice Health vs Regeneron

Side-by-side comparison of AI visibility scores, market position, and capabilities

Regeneron leads in AI visibility (75 vs 37)
Aevice Health logo

Aevice Health

EmergingBioTech

Digital Health

Aevice Health raised $30M Series B in 2025 for its AI-powered wearable respiratory monitor that continuously tracks wheezing, coughing, and breathing abnormalities in asthma and COPD patients.

AI VisibilityBeta
Overall Score
D37
Category Rank
#1 of 1
AI Consensus
65%
Trend
up
Per Platform
ChatGPT
43
Perplexity
46
Gemini
43

About

Aevice Health develops wearable respiratory monitoring technology that uses AI to analyze breath sounds captured continuously from a chest-worn device. The AeviceMD system detects wheezing, coughing, and abnormal breathing patterns in real time, enabling early warning of asthma attacks and COPD exacerbations before they require emergency care. The device transmits data to a smartphone app and clinical dashboard for remote monitoring by pulmonologists.

Full profile
Regeneron logo

Regeneron

LeaderLife Sciences & BioTech

Biopharmaceuticals

Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.

AI VisibilityBeta
Overall Score
B75
Category Rank
#2 of 2
AI Consensus
73%
Trend
up
Per Platform
ChatGPT
72
Perplexity
76
Gemini
84

About

Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.

Full profile

AI Visibility Head-to-Head

37
Overall Score
75
#1
Category Rank
#2
65
AI Consensus
73
up
Trend
up
43
ChatGPT
72
46
Perplexity
76
43
Gemini
84
32
Claude
77
36
Grok
79

Key Details

Category
Digital Health
Biopharmaceuticals
Tier
Emerging
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Aevice Health
Digital Health
Only Regeneron
Biopharmaceuticals

Integrations

Only Regeneron

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.